Posted by Michael Wonder on 06 Mar 2024
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic treatments
6 March 2024 - NICE has published final evidence-based recommendations on the use of epcoritamab (Tepkinly) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after 2two or more systemic treatments.
Epcoritamab is recommended as an option for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic treatments, only if they have had polatuzumab vedotin, or if the use of polatuzumab vedotin is contra-indicated or not tolerated, and AbbVie provides epcoritamab according to the commercial arrangement.
